CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleLevered free cash flow is $20.77M, above the global median of $18.73M
- FinancialsAltman Z-Score 4.39: safe zone
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.49%Below 5Y avg (0.70%)
Annual Rate
CNY 0.10Paid annual
Payout Ratio
13.3%Sustainable
Last Ex-Dividend
Sep 16, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.81BCNY419.39M · vs all stocks (USD)
Trailing P/E
35.50xRevenue (TTM)
989.42MCNY147.64M · vs all stocks (USD)
Profit Margin
7.94%52-Week Change
-11.23%vs all stocks
Market Capitalization
2.81BCNY419.39M · vs all stocks (USD)
Enterprise Value
1.70BCNY252.97M · vs all stocks (USD)
Trailing P/E
35.50xPrice to Sales (TTM)
2.84xPrice to Book (MRQ)
1.65xEnterprise to Revenue
1.71xEnterprise to EBITDA
12.33xGross Margin
60.91%Profit Margin
7.94%Operating Margin
16.50%Return on Assets (TTM)
2.61%Return on Equity (TTM)
4.60%Revenue (TTM)
989.42MCNY147.64M · vs all stocks (USD)
Revenue per Share (TTM)
7.29CNYUpdated Sep 19, 2026Quarterly Revenue Growth
-38.20%Gross Profit (TTM)
542.49MCNY80.95M · vs all stocks (USD)
EBITDA (TTM)
124.30MCNY18.55M · vs all stocks (USD)
Net Income (TTM)
78.52MCNY11.72M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-28.60%Operating Cash Flow (TTM)
176.91MCNY26.40M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
139.16MCNY20.77M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.1000CNYUpdated Sep 19, 2026Trailing Annual Dividend Yield
0.49%vs all stocks
5-Year Average Dividend Yield
0.70%vs all stocks
Payout Ratio
13.32%Minority Interest (Equity)
2.20MCNYFY2025 · Dec 31, 2025Revenue
1.14BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
549.08MCNYFY2025 · Dec 31, 2025Gross Profit
591.79MCNYFY2025 · Dec 31, 2025Operating Income
122.28MCNY18.25M · vs all stocks (USD)
Pre-tax Income
108.95MCNYFY2025 · Dec 31, 2025Income Tax Expense
12.93MCNYFY2025 · Dec 31, 2025Net Income
96.02MCNYFY2025 · Dec 31, 2025EBIT
111.14MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
172.28MCNYFY2025 · Dec 31, 2025Research & Development
53.11MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
334.71MCNYFY2025 · Dec 31, 2025Other Operating Expenses
12.29MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
14.55MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
2.18MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.9200CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.9200CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
104.65MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
104.65MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
96.02MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
257.86KCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-42.37MCNYFY2025 · Dec 31, 2025Free Cash Flow
-84.50MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.09BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
96.02MCNYFY2025 · Dec 31, 2025Other Non-cash Items
2.74MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-121.29MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-19.85MCNYFY2025 · Dec 31, 2025Capital Expenditures
-42.12MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-42.12MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
50.00MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-101.00MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-43.89MCNYFY2025 · Dec 31, 2025Other Financing Charges
-478.47KCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-95.37MCNYFY2025 · Dec 31, 2025Shares Outstanding
138.17MSharesUpdated Sep 19, 2026Float Shares
85.06MSharesUpdated Sep 19, 2026% Held by Insiders
39.33%vs all stocks
% Held by Institutions
4.93%vs all stocks
Total Cash (MRQ)
1.20BCNY178.62M · vs all stocks (USD)
Total Cash per Share (MRQ)
8.63CNYUpdated Sep 19, 2026Total Debt (MRQ)
53.37MCNY7.96M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0307xCurrent Ratio (MRQ)
3.66xBook Value per Share (MRQ)
12.52CNYUpdated Sep 19, 2026Total Assets
2.32BCNY346.61M · vs all stocks (USD)
Total Current Assets
1.80BCNYFY2025 · Dec 31, 2025Total Liabilities
633.75MCNYFY2025 · Dec 31, 2025Total Non-current Assets
520.01MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
109.60MCNYFY2025 · Dec 31, 2025Total Current Liabilities
524.15MCNYFY2025 · Dec 31, 2025Cash
1.09BCNYFY2025 · Dec 31, 2025Cash Equivalents
65.78KCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.09BCNYFY2025 · Dec 31, 2025Accounts Receivable
423.39MCNYFY2025 · Dec 31, 2025Inventory
110.82MCNYFY2025 · Dec 31, 2025Accounts Payable
127.57MCNYFY2025 · Dec 31, 2025Short-term Debt
98.88MCNYFY2025 · Dec 31, 2025Other Current Liabilities
523.51KCNYFY2025 · Dec 31, 2025Long-term Debt
1.95MCNYFY2025 · Dec 31, 2025Common Stock (Book)
106.28MCNYFY2025 · Dec 31, 2025Retained Earnings
703.10MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.69BCNY252.04M · vs all stocks (USD)
Treasury Stock
25.08MCNYFY2025 · Dec 31, 202552-Week Low
19.00CNYUpdated Sep 19, 202652-Week High
32.98CNYUpdated Sep 19, 202652-Week Change
-11.23%vs all stocks
50-Day MA
21.76CNYUpdated Sep 19, 2026200-Day MA
23.98CNYUpdated Sep 19, 2026Avg 10-Day Volume
1.97MSharesUpdated Sep 19, 2026Avg 30-Day Volume
3.00MSharesUpdated Sep 19, 2026Diluted EPS (TTM)
0.5800CNYUpdated Sep 19, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.61Profit Margin: 0.08
Financial Health
Altman Z-Score 4.39: safe zoneNotable
Altman Z-Score: 4.39
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Levered free cash flow is $20.77M, above the global median of $18.73MNotable
Levered free cash flow (USD): 20,765,646.202Global Median: 18,729,043.027
Companies that share the same coordination system — how they create, deliver, or capture value.
Deva Holding A.S.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Canopy Growth Corporation
Tier 1ProductionApproval-Gated PipelineFlowRule
Jiangxi Synergy Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Orum Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Kyverna Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Allgens Medical Technology Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Tuoxin Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang East-Asia Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Anhui Fengyuan Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Novartis India Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow